NN&I - May 2010
Facility Management www.nephronline.comMay 2010 Nephrology News & Issues 47 Pharmacy. Am J Kidney Dis. 2005;45:1105-18.9. Erickson AL, Szumita PM, Cotugno MC. Imple-mentation of clinical pharmacy services in a dialysis unit. Am J Health Syst Pharm. 2008;65:2011-3.10. Pai AB, Boyd A, Chavez A, et al. Health-related quality of life is maintained in hemodialysis patients receiving pharmaceutical care: A two-year randomized, controlled study. Hemodial Int. 2009;13:72-9.11. Manley HJ, Drayer DK, Muther RS. Medication-related problem type and appearance rate in ambulatory hemodialysis patients. BMC Nephrol. 2003;4:10.12. Pai AB, Boyd A, Depczynski J, et al. Reduced drug use and hospitalization rates in patients undergoing hemodialysis who received pharma-ceutical care: a 2 year randomized controlled study. Pharmacotherapy 2009;29:1433-40. 13. Joy MS, Matzke GR. Nephrology pharmacy: historical reflections and future challenges. Ann Pharmacother 2007;41:1884-614. Mendelssohn DC, Toffelmire EB, Levin A. Attitudes of Canadian nephrologists toward mul- tidisciplinary team-based CKD clinic care. Am J Kidney Dis. 2006;47:277-84.15. Bennett RE, DeHart RM, Lauderdale SA. Survey of care provided by ambulatory care pharmacists to patients with chronic kidney disease. Am J Health Syst Pharm. 2006;63:2123-7.16. Grabe DW. Drug related problems in the end stage renal disease population. Medscape Pharmacists. Posted 10/23/2000. Available at www. medscape.com/viewarticle/408570_6. (Accessed April 6, 2010)17. Hall K, Wilgosh C, Editors. 2007/08 Hospital pharmacy in Canada report. Available at . Canada.: 2007Available at www.lillyhospitalsurvey.ca. (Accessed April 6, 2010)18. Centres for Medicare and Medicaid Services. Conditions for coverage for end stage renal dis-ease facilities; final rule. Federal Register. 2008;73(73):20399-427.19. Canada Health Act. Ottawa, ON: Health Canada. 2004 October 1, 2004. Available from: http://www. hc-sc.gc.ca/hcs-sss/medi-assur/cha-lcs/index-eng.php. (accessed August 17, 2009) 20. Hepler CD. Pharmaceutical care. Pharm World Sci. 1996;18:233-5. 21. Wazny LD, Raymond CB, Lesperance EM et al. Are CSN and NKF-K/DOQI mineral metabolism T h e r e ' s n o p l a c e l i k e N e p h r o l o g y N e w s & I s s u e s i s a C h a m p i o n S p o n s o r o f H o m e D i a l y s i s C e n t r a l guidelines for hemodialysis patients achievable? Results from a provincial renal program. CANNT J. 2008;18:36,41, 44-50 22. Raymond CB, Wazny LD, Vercaigne LM, et al. Conversion from epoetin alfa to darbepoetin alfa within the Manitoba renal program: Evaluation of dose ratios. CANNT J. 2008;18:39-43. 23. Vercaigne LM, Zelenitsky SA, Findlay I, et al. An in vitro evaluation of the antibiotic/heparin lock to sterilize central venous haemodialysis catheters. J Antimicrob Chemother. 2002;49:693-6. 24. Sood A, Wazny L, Raymond C, et al. In: Sodium thiosulfate-based treatment in calcific uremic arte- riolopathy: A provincial case series. Presented at the Canadian Society for Nephrologists Annual Meeting. Edmonton, AB; 2009 May 11. 25. Hildebrand A, Arsenio J, Coudiere R, et al. In: Process engineering better chronic kidney disease care: Design parameters in quality and efficiency Presented at the Canadian Society for Nephrologists Annual Meeting. Edmonton, AB; 2009 May 12, 2009 26. Manley HJ, Carroll C. The clinical and economic impact of pharmaceutical care in end stage renal disease patients. Seminar Dial 2002; 15:45-9 Pharmaco Facility_6.indd 47 4/19/10 3:27:44 PM
You must have JavaScript enabled to view digital editions.
